Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer

Autor: Louise Faaborg, Rikke Fredslund Andersen, Marianne Waldstrøm, Jon Røikjær Henriksen, Parvin Adimi, Anders Jakobsen, Karina Dahl Steffensen

Publikováno v: Cancers; Volume 14; Issue 7; Pages: 1766
Faaborg, L, Andersen, R F, Waldstrøm, M, Henriksen, J R, Adimi, P, Jakobsen, A & Steffensen, K D 2022, ' Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer ', Cancers, vol. 14, no. 7, 1766 . https://doi.org/10.3390/cancers14071766

Methylated Homeobox A9 circulating tumor DNA (meth-HOXA9) has been suggested as a blood-based biomarker in epithelial ovarian cancer (EOC), although its prognostic significance remains unproven. The aim of the present study was to investigate the pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9622bcf5351abd3b8c637cccdd429c0d

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

Autor: Rikke Fredslund Andersen, Caroline Brenner Thomsen, Parvin Adimi, Karina Dahl Steffensen, Anders Jakobsen

Publikováno v: Thomsen, C B, Andersen, R F, Steffensen, K D, Adimi, P & Jakobsen, A 2019, ' Delta tocotrienol in recurrent ovarian cancer. A phase II trial ', Pharmacological Research, vol. 141, pp. 392-396 . https://doi.org/10.1016/j.phrs.2019.01.017

Delta tocotrienol has anti-neoplastic activity as demonstrated in several in-vitro and in-vivo investigations. The effect relies on inhibition of different pathways. It also has antiangiogenic activity, and an additive effect to bevacizumab may be ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::419faf089eb1a48fd31f4a9d8e95f5ce
https://doi.org/10.1016/j.phrs.2019.01.017

Cabazitaxel - Α treatment option in recurrent platinum-resistant ovarian cancer

Autor: Karina Dahl Steffensen, Parvin Adimi, Christine Vestergaard Madsen, Anders Jakobsen

Publikováno v: Vestergaard Madsen, C, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2020, ' Cabazitaxel-Α treatment option in recurrent platinum-resistant ovarian cancer ', Anticancer Research, vol. 40, no. 9, pp. 5255-5261 . https://doi.org/10.21873/anticanres.14529
Madsen, C V, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2018, ' CABAZITAXEL-A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER ', 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018), Kyoto, Japan, 14/09/2018-16/09/2018 . < https://igcs2018.com/scientific-information/interactive-program#.W7R11dTU-70 >
University of Southern Denmark

Background and Aims:Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of chemo-resistance. Cabazitaxel is a new taxane that has demonstrated effect in prostatic cancer patients resistant to Docetaxel.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5cf13075695ccbe7745d4b757267d78
https://portal.findresearcher.sdu.dk/da/publications/90e952c0-9af8-4e25-8bf2-3431eeb1752f

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

Autor: Anders Jakobsen, Karina Dahl Steffensen, Jon Røikjær Henriksen, Parvin Adimi, Marianne Waldstrøm, Frede Donskov, Line Nederby

Publikováno v: Journal of Ovarian Research
Henriksen, J R, Nederby, L, Donskov, F, Waldstrøm, M, Adimi, P, Jakobsen, A & Steffensen, K D 2020, ' Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy ', Journal of Ovarian Research, vol. 13, no. 1, 59 . https://doi.org/10.1186/s13048-020-00661-4
Henriksen, J R, Nederby, L, Donskov, F, Waldstrøm, M, Adimi, P, Jakobsen, A & Steffensen, K D 2020, ' Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy ', Journal of Ovarian Research, vol. 13, 59 . https://doi.org/10.1186/s13048-020-00661-4
Journal of Ovarian Research, Vol 13, Iss 1, Pp 1-9 (2020)

Purpose Biomarkers are needed to guide treatment decisions in recurrent ovarian cancer, as a high proportion of patients do not benefit from treatments. Data on immune subsets in patients receiving chemotherapy are scarce. We investigated the impact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41794e4328e2d6a85fc89b98ccc94616
https://doi.org/10.1186/s13048-020-00661-4

59 Natural killer cells and treatment effect in recurrent ovarian cancer

Autor: Frede Donskov, Parvin Adimi, Line Nederby, K. Dahl Steffensen, Marianne Waldstrøm, Jon Roeikjaer Henriksen, A. Jakobsen

Publikováno v: Regional plenary.

Objectives Treatment of ovarian cancer (OC) is challenged by advanced stage at diagnosis, development of resistance to chemotherapy resulting in low response rates. Natural killer (NK) cells are a subset of lymphocytes with antitumor capabilities how

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb8c52aa1ea46b945ad6b934d55cb0c0
https://doi.org/10.1136/ijgc-2019-igcs.59